<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:26:42Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:1636660" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:1636660</identifier><datestamp>2006-11-16</datestamp><setSpec>retrovir</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://dtd.nlm.nih.gov/ns/archiving/2.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://dtd.nlm.nih.gov/ns/archiving/2.3/ https://dtd.nlm.nih.gov/archiving/2.3/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Retrovirology</journal-id>
      <journal-title>Retrovirology</journal-title>
      <issn pub-type="epub">1742-4690</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC1636660</article-id>
      <article-id pub-id-type="pmcid">PMC1636660</article-id>
      <article-id pub-id-type="pmc-uid">1636660</article-id>
      <article-id pub-id-type="pmid">17092330</article-id>
      <article-id pub-id-type="publisher-id">1742-4690-3-81</article-id>
      <article-id pub-id-type="pmid">17092330</article-id>
      <article-id pub-id-type="doi">10.1186/1742-4690-3-81</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" contrib-type="author">
          <name>
            <surname>SÃ¡ez-CiriÃ³n</surname>
            <given-names>Asier</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>asiersc@pasteur.fr</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>Versmisse</surname>
            <given-names>Pierre</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>pversmis@pasteur.fr</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Truong</surname>
            <given-names>Lien X</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>xuanlien@hcm.vnn.vn</email>
        </contrib>
        <contrib id="A4" contrib-type="author">
          <name>
            <surname>Chakrabarti</surname>
            <given-names>Lisa A</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>chakra@pasteur.fr</email>
        </contrib>
        <contrib id="A5" contrib-type="author">
          <name>
            <surname>Carpentier</surname>
            <given-names>Wassila</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>carpenti@chups.jussieu.fr</email>
        </contrib>
        <contrib id="A6" contrib-type="author">
          <name>
            <surname>BarrÃ©-Sinoussi</surname>
            <given-names>FranÃ§oise</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>fbarre@pasteur.fr</email>
        </contrib>
        <contrib id="A7" contrib-type="author">
          <name>
            <surname>Scott-Algara</surname>
            <given-names>Daniel</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>scott@pasteur.fr</email>
        </contrib>
        <contrib id="A8" corresp="yes" contrib-type="author">
          <name>
            <surname>Pancino</surname>
            <given-names>Gianfranco</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>gpancino@pasteur.fr</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>UnitÃ© de RÃ©gulation des Infections RÃ©trovirales, Institut Pasteur, Paris, France</aff>
      <aff id="I2"><label>2</label>Retrovirology and Viral Hepatitis Laboratory, Institut Pasteur, Ho Chi Minh City, Vietnam</aff>
      <aff id="I3"><label>3</label>Laboratoire de PathogÃ©nie Virale MolÃ©culaire, Institut Pasteur, Paris, France</aff>
      <aff id="I4"><label>4</label>Laboratoire d'Immunologie Cellulaire, UR INSERM 543, FacultÃ© de MÃ©decine PitiÃ©-SalpÃ©triÃ¨re, Paris, France</aff>
      <aff id="I5"><label>5</label>UnitÃ© d'ImmunogÃ©nÃ©tique Cellulaire, Institut Pasteur, Paris, France</aff>
      <pub-date pub-type="collection">
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>11</month>
        <year>2006</year>
      </pub-date>
      <volume>3</volume>
      <fpage>81</fpage>
      <lpage>81</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.retrovirology.com/content/3/1/81"/>
      <history>
        <date date-type="received">
          <day>3</day>
          <month>8</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>11</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2006 SÃ¡ez-CiriÃ³n et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2006</copyright-year>
        <copyright-holder>SÃ¡ez-CiriÃ³n et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
          <!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               S&#x000e1;ez-Ciri&#x000f3;n
               Asier
               
               asiersc@pasteur.fr
            </dc:author><dc:title>
            Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks
         </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Retrovirology 3(1): 81-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1742-4690(2006)3:1&#x0003c;81&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1742-4690</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>-->
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>We have previously reported that CD4 T cells from some exposed uninfected (EU) Vietnamese intravenous drug users are relatively resistant to HIV infection in vitro. Here, we further characterized the restriction of viral replication in CD4 T cells from five EUs and assessed its persistence in serial samples.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>CD4 T cells and/or PBMC sampled during a period of between 2 and 6 years were challenged with replication-competent HIV-1 and other retroviral particles pseudotyped with envelope proteins of various tropisms. CCR5 expression and function in resistant CD4 T cells was evaluated. The step at which HIV-1 replication is restricted was investigated by real-time PCR quantification of HIV-1 reverse transcripts.</p>
          <p>We identified three patterns of durable HIV-1 restriction in EU CD4 T cells. CD4 T cells from four of the five EU subjects were resistant to HIV-1 R5 infection. In two cases this resistance was associated with low CCR5 surface expression, which was itself associated with heterozygous CCR5 mutations. In the other two cases, CD4 T cells were resistant to HIV-1 R5 infection despite normal CCR5 expression and signaling function, and normal Î²-chemokine secretion upon CD4 T cell activation. Instead, restriction appeared to be due to enhanced CD4 T cell sensitivity to Î²-chemokines in these two subjects. In the fifth EU subject the restriction involved post-entry steps of viral replication and affected not only HIV-1 but also other lentiviruses. The restriction was not overcome by a high viral inoculum, suggesting that it was not mediated by a saturable inhibitory factor.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Various constitutive mechanisms of CD4 T cell resistance to HIV-1 infection, affecting entry or post-entry steps of viral replication, are associated with resistance to HIV-1 in subjects who remain uninfected despite long-term high-risk behavior.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Cellular susceptibility to human immunodeficiency virus (HIV) infection in vitro varies widely among individuals [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Both host genetic and acquired mechanisms regulate HIV-1 replication. HIV requires numerous host cell factors for efficient replication [<xref ref-type="bibr" rid="B3">3</xref>]. The recent discovery of several molecules endowed with antiretroviral activity in mice and primates underlines the contribution of innate intracellular resistance to infection by HIV and other retroviruses [<xref ref-type="bibr" rid="B4">4</xref>]. Some of these molecules, such as the cytidine deaminase APOBEC3G, have been implicated in the restriction of HIV-1 replication in resting human T cells [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Resistance to HIV-1 infection in vivo has not so far been linked to the expression or genetic polymorphism of these restriction factors [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], but the efficiency of viral replication is likely to be determined in large part by the balance between required factors and restrictive factors.</p>
      <p>Some individuals who are highly exposed to HIV-1 and yet remain uninfected (exposed uninfected individuals, EU) are likely to be naturally resistant to infection. Relative resistance of CD4 T cells and/or macrophages to HIV-1 infection has been reported in selected EUs [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. This resistance was usually restricted to HIV-1 isolates using the CCR5 chemokine receptor (R5 isolates) to enter target cells [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Invalidating mutations in the CCR5 gene confer resistance to HIV-1 R5 infection in vitro [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>], and the CCR5Î32 homozygous genotype is associated with protection against HIV-1 acquisition in Caucasians [<xref ref-type="bibr" rid="B17">17</xref>]. Reduced in vitro susceptibility to HIV-1 R5 of EU CD4 T cells bearing wild-type CCR5 has been linked to low CCR5 expression on the target cell surface and/or to increased secretion of natural CCR5 ligands â the Î²-chemokines RANTES/CCL5, MIP-1Î±/CCL3 and MIP-1Î²/CCL4 [<xref ref-type="bibr" rid="B12">12</xref>] â by CD4 or CD8 T lymphocytes [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. Infection of CD4 T cells may also be inhibited by unidentified soluble antiviral factors secreted by CD8 T lymphocytes [<xref ref-type="bibr" rid="B21">21</xref>]. Nevertheless, CD8 T cell associated resistance to HIV-1 infection was reported to wane in EUs who reduced their high-risk behavior, suggesting that reduced exposure led to decreased CD8 T cell antiviral immunity [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>].</p>
      <p>We have previously shown that some Vietnamese intravenous drug users who remained uninfected by HIV despite more than 15 years of drug use (resulting in a high prevalence of other blood-borne viral infections) have low CD4 T cell permissiveness to HIV infection in vitro [<xref ref-type="bibr" rid="B11">11</xref>]. In order to identify the mechanisms of CD4 T cell resistance in this population, we investigated the characteristics of HIV-1 restriction in five Vietnamese EUs who were monitored for between 2 and 6 years. We identified three different patterns of restriction, affecting viral entry or post-entry steps. We also found that CD4 T cell resistance to HIV was stable over time.</p>
    </sec>
    <sec>
      <title>Results</title>
      <sec>
        <title>CD4 T cell resistance to single-round HIV-1 infection in Vietnamese EUs</title>
        <p>In a previous study of Vietnamese IDU EUs we identified some individuals whose CD4 T lymphocytes showed reduced susceptibility to in vitro infection by replicative strains of HIV-1 [<xref ref-type="bibr" rid="B11">11</xref>]. HIV-1 replication in CD4 T cells from three EUs (W276, W278 and B195) was far less efficient than in CD4 T cells from healthy controls. Analysis of the <italic>CCR5 </italic>gene in the same population revealed heterozygous mutations in some subjects [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. In two cases (B184 and W336) the mutations in CCR5 were associated with reduced co-receptor function in transfected cell lines [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B26">26</xref>], but the effect of these mutations in heterozygous primary cells was not assessed.</p>
        <p>CD4 T cells from the five EUs studied here (W276, W278, B195, B184 and W336; Table <xref ref-type="table" rid="T1">1</xref>) had reduced susceptibility to infectious strains of HIV-1 (data not shown and [<xref ref-type="bibr" rid="B11">11</xref>]; see Materials and Methods for corresponding subjects designations). We used single-round infection with envelope-pseudotyped HIV-1 NL4.3Î env particles bearing the luciferase reporter gene to investigate whether the reduced HIV-1 susceptibility of the EUs' CD4 T cells was detectable during the first cycle of viral replication (fig. <xref ref-type="fig" rid="F1">1</xref>). In four out of five cases (W278, B195, B184, W336), CD4 T cells were less susceptible to infection by a CCR5-tropic (R5) HIV-1 pseudotype (HIV-BaL), while they were permissive to infection by a CXCR4-tropic (X4) HIV-1 pseudotype (HIV-HxB2) and to HIV-1 particles pseudotyped with the G protein from vesicular stomatitis virus (HIV-VSVG), which has a ubiquitous (pantropic) receptor and uses an endocytic entry pathway [<xref ref-type="bibr" rid="B27">27</xref>] (fig. <xref ref-type="fig" rid="F1">1</xref>). These results showed that the CD4 T cells of the EUs with heterozygous mutations in CCR5 (B184 and W336) were less susceptible to infection by HIV-1 R5 pseudotype and confirmed our previous observation that HIV-1 restriction in subjects W278 and B195 is specific to R5 viruses [<xref ref-type="bibr" rid="B11">11</xref>]. As shown, single-round infection of CD4 T cell from these four EUs was partially reduced. Interestingly, when replication-competent HIV-1 strains were used, inhibition of infection was much stronger (data not shown and [<xref ref-type="bibr" rid="B11">11</xref>]), suggesting that the restrictions observed during the first round of HIV-1 replication are amplified during subsequent cycles.</p>
        <table-wrap position="float" id="T1">
          <label>Table 1</label>
          <caption>
            <p>Characteristics of the study subjects.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <td align="center">EU code</td>
                <td align="center">Year of birth</td>
                <td align="center">Sex</td>
                <td align="center">IDU started</td>
                <td align="center">Risk ended</td>
                <td align="center" colspan="4">Serology</td>
                <td align="center">Enrollment</td>
                <td align="center">Follow-up ended</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td align="center">HBc</td>
                <td align="center">HBs</td>
                <td align="center">HCV</td>
                <td align="center">HTLV</td>
                <td align="center">Year</td>
                <td align="center">Year</td>
              </tr>
              <tr>
                <td colspan="11">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="center">W276</td>
                <td align="center">1960</td>
                <td align="center">M</td>
                <td align="center">1979</td>
                <td align="center">2003</td>
                <td align="center">+</td>
                <td align="center">-</td>
                <td align="center">+</td>
                <td align="center">+</td>
                <td align="center">1996</td>
                <td align="center">2004</td>
              </tr>
              <tr>
                <td align="center">W278</td>
                <td align="center">1955</td>
                <td align="center">M</td>
                <td align="center">1978</td>
                <td align="center">2000</td>
                <td align="center">-</td>
                <td align="center">-</td>
                <td align="center">+</td>
                <td align="center">+</td>
                <td align="center">1996</td>
                <td align="center">2004</td>
              </tr>
              <tr>
                <td align="center">W336</td>
                <td align="center">1958</td>
                <td align="center">M</td>
                <td align="center">1975</td>
                <td align="center">2001</td>
                <td align="center">+</td>
                <td align="center">-</td>
                <td align="center">+</td>
                <td align="center">+</td>
                <td align="center">1996</td>
                <td align="center">2004</td>
              </tr>
              <tr>
                <td align="center">B184</td>
                <td align="center">1951</td>
                <td align="center">M</td>
                <td align="center">1972</td>
                <td align="center">2003</td>
                <td align="center">+</td>
                <td align="center">-</td>
                <td align="center">+</td>
                <td align="center">+</td>
                <td align="center">1998</td>
                <td align="center">2004</td>
              </tr>
              <tr>
                <td align="center">B195</td>
                <td align="center">1949</td>
                <td align="center">F</td>
                <td align="center">1972</td>
                <td align="center">Unknown</td>
                <td align="center">+</td>
                <td align="center">-</td>
                <td align="center">+</td>
                <td align="center">-</td>
                <td align="center">1998</td>
                <td align="center">1999</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>HBc: anti-hepatitis B virus antibodies; HBs: hepatitis B antigen; HCV: hepatitis C virus; HTLV: human T cell leukaemia/lymphoma virus (I and/or II)</p>
          </table-wrap-foot>
        </table-wrap>
        <fig position="float" id="F1">
          <label>Figure 1</label>
          <caption>
            <p><bold>Reduced susceptibility of EU CD4 T cells to infection by pseudotyped HIV-1</bold>. CD4 T cells were challenged with HIV-1 particles pseudotyped with R5 (BaL) (white bars), X4 (HxB2) (black bars) or pantropic (VSV-G) (patterned bars) envelope glycoproteins. Results (mean of three experiments) are expressed as relative luciferase activity in cell lysates three days after infection. Luciferase activity in cell lysates from a representative control was attributed a value of 100%. Error bars representing standard deviation are shown in each case.</p>
          </caption>
          <graphic xlink:href="1742-4690-3-81-1"/>
        </fig>
        <p>Remarkably, CD4 T cells from subject W276 were resistant to both R5 and X4 HIV-1 pseudotypes and also to the HIV-VSVG pseudotype. These results indicated that the restriction was independent not only of HIV coreceptors, as previously shown [<xref ref-type="bibr" rid="B11">11</xref>], but also of the entry pathway used by the virus (fig. <xref ref-type="fig" rid="F1">1</xref>).</p>
      </sec>
      <sec>
        <title>CCR5 expression and function in HIV-1 R5 restricted cells</title>
        <p>As already mentioned, CCR5 heterozygous mutations had been detected in subjects B184 and W336 (G106R and C178R respectively) [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. These (or equivalent) mutations, when present in the homozygous state in transfected cell lines, affect the receptor conformation and both CCR5 membrane trafficking and function [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. However, CCR5 surface expression by these two EUs' primary CD4 T cells has not been evaluated before.</p>
        <p>Flow cytometry of R5-restricted CD4 T cells revealed that the percentage of CD4 T cells expressing detectable surface CCR5 was far lower in the two EUs carrying heterozygous CCR5 mutations (B184 and W336) than in controls expressing the wild-type (wt) CCR5 molecule (fig. <xref ref-type="fig" rid="F2">2A</xref>). In contrast, no such difference was found, in either the percentage (fig. <xref ref-type="fig" rid="F2">2A</xref>) or the mean fluorescence intensity (MFI), in the other two EUs (W278 and B195) who both had wt CCR5 (the CCR5 MFI was 1.38 and 1.21 in subjects W278 and B195, respectively, and 1.39 Â± 0.24, mean Â± SD, in five CCR5-wt controls).</p>
        <fig position="float" id="F2">
          <label>Figure 2</label>
          <caption>
            <p><bold>R5 tropic HIV-1 restriction in CD4 T cells from four EUs</bold>. <bold>A. </bold>Relative infection by the HIV-BaL pseudotype (white bars; n = 3, mean Â± SD) of CD4 T cells from the EUs B184, W336, B195 and W278, and percentage of cells with detectable surface expression of the CCR5 co-receptor (black bars, one experiment shown, representative of two different experiments). <bold>B. </bold>CCR5-mediated actin polymerisation in CD4 T cells from W278 (â) B195 (â¼) (top left and right panels respectively) and four different CCR5-wt controls. Cells from a control donor (bottom right panel) were also treated with TAK-779 (2 Î¼M) for 60 minutes before RANTES stimulation (open circles). Results show the kinetics of actin polymerization triggered by RANTES stimulation, as measured by the incorporation of the FITC-phalloidin probe. The percentage of actin polymerization is expressed as follows: [(MFI after ligand addition)/(MFI before ligand addition)] Ã 100. 100% corresponds to the baseline level of unstimulated cells. <bold>C. </bold>Relative infection of CD4 T cells from subjects W278 (white bars) and B195 (black bars) by R5 (HIV-BaL; HIV-JRFL; HIV-YU2), X4 (HIV-HxB2) and pantropic (HIV-VSVG) pseudotypes (n = 3, mean Â± SD). The luciferase activity in cell lysates from one representative control was attributed a value of 100%.</p>
          </caption>
          <graphic xlink:href="1742-4690-3-81-2"/>
        </fig>
        <p>Therefore, the low surface expression of CCR5 on CD4 T cells from EUs B184 and W336 is likely linked to CCR5 mutations and appears to affect R5 virus entry into target cells. However, HIV R5 replication in CD4 T cells from subjects W278 and B195 was restricted despite normal CCR5 surface expression (fig. <xref ref-type="fig" rid="F2">2A</xref>). We therefore examined whether CCR5 function was impaired in the CD4 T cells of these two subjects, affecting signaling events potentially involved in HIV-1 replication [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>].</p>
        <p>As actin cytoskeleton reorganization is a major characteristic of chemokine responses, we analyzed CCR5-mediated actin polymerization in CD4 T cells from subjects W278 and B195. RANTES stimulation of CD4 T cells induced a rapid increase in the F-actin content of cells from the two EUs and from four CCR5-wt controls (fig. <xref ref-type="fig" rid="F2">2B</xref>). The peak responses occurred 15â30 s after stimulation, in keeping with a fully functional chemoreceptor [<xref ref-type="bibr" rid="B30">30</xref>]. Cell pretreatment with the CCR5 inhibitor TAK-779 [<xref ref-type="bibr" rid="B31">31</xref>] abrogated actin polymerization.</p>
        <p>The restriction in CD4 T cells from subjects W278 and B195 affected HIV-1 viruses pseudotyped with different R5 tropic envelopes (JRFL [<xref ref-type="bibr" rid="B32">32</xref>] and YU2 [<xref ref-type="bibr" rid="B33">33</xref>]) (fig. <xref ref-type="fig" rid="F2">2C</xref>). These results confirmed that the restriction in W278 and B195 CD4 T cells is specific for the CCR5 entry pathway and indicated that it is independent of CCR5 expression and function.</p>
      </sec>
      <sec>
        <title>Abrogation of viral restriction in cells from subjects W278 and B195 with anti-Î²-chemokines</title>
        <p>R5 virus entry into CD4 T cells can be blocked by endogenously produced Î²-chemokines [<xref ref-type="bibr" rid="B20">20</xref>]. We therefore investigated whether the restriction of HIV-1 R5 replication in CD4 T cells from subjects W278 and B195 could be overcome by neutralizing monoclonal antibodies (MAbs) to RANTES, MIP1Î± and MIP1Î². The addition of anti-Î²-chemokine mAbs, but not of irrelevant IgGs, strongly enhanced the infection of both W278 and B195 cells by the HIV-1 pseudotype, while no significant enhancement was observed in CCR5-wt control cells with similar CCR5 surface expression (fig. <xref ref-type="fig" rid="F3">3A</xref>). These results suggest that endogenously produced Î²-chemokines may be responsible for the inhibition of HIV-1 infection in CD4 T cells from subjects W278 and B195.</p>
        <fig position="float" id="F3">
          <label>Figure 3</label>
          <caption>
            <p><bold>Role of Î²-chemokines in HIV-1 restriction in CD4 T cells from subjects W278 and B195</bold>. <bold>A. </bold>CD4 T cells from subjects W278 and B195 were challenged with the HIV-BaL pseudotype in the absence (white bars) or presence of a combination of neutralizing anti-RANTES (5 Î¼g/ml), anti-MIP1Î± (15 Î¼g/ml) and anti-MIP1Î² (25 Î¼g/ml) (R&amp;D systems, France) mAbs (black bars) or with an isotype control antibody (45 Î¼g/ml) (patterned bars). The antibodies were added 30 minutes before challenge and maintained throughout the time course of infection. Results are expressed as relative luciferase activity, compared to the maximal activity found in the presence of the neutralizing anti-Î²-chemokines in each case, and are the mean of three independent infections Â± standard deviation. ** Significant difference (P &lt; 0.001 and P = 0.008 for W278 and B195, respectively, independent sample t-test). <bold>B. </bold>Challenge with the HIV-BaL pseudotype (n = 3, mean Â± SD) of CD4 T cells from EUs W278 and B195, stimulated with PHA three days before (white bars) or two hours after (black bars) challenge. Luciferase activity in cell lysates from a representative control challenged in the same conditions was attributed a value of 100%. <bold>C. </bold>Sensitivity of CD4 T cells to recombinant chemokines. Non mitogen-stimulated CD4 T cells from EU B195 (filled circles) and one control (open squares) were exposed to various concentrations of a mixture of the recombinant Î²-chemokines RANTES, MIP-1Î± and MIP-1Î² (R&amp;D systems, France) for 30 minutes prior to and during infection. The mixtures contained the three chemokines at concentrations ranging from 500 ng to 2 ng each. Results (n = 3, mean Â± SD) are expressed as luciferase activity per second in cell lysates. Points were fitted to a four-parameter logistic curve (r<sup>2 </sup>were 0.845 and 0.826 for B195 and control, respectively). Statistical analysis and curve-fitting were performed with Sigmaplot software (Systat Software, Inc, CA, USA).</p>
          </caption>
          <graphic xlink:href="1742-4690-3-81-3"/>
        </fig>
        <p>When we challenged CD4 T cells with BaL pseudotyped HIV in a setting of weak Î²-chemokine production (before PHA and IL2 activation; &lt;3 ng) we found that infection was as efficient in the two EUs as in controls (fig. <xref ref-type="fig" rid="F3">3B</xref>). This was consistent with the hypothesis that the inhibition of HIV-1 infection in PHA-activated CD4 T cells from subjects W278 and B195 involved chemokines produced upon cell activation. However, quantification of Î²-chemokines produced by PHA-activated CD4 T cells at the time of HIV-1 infection (three days after PHA stimulation) showed no significant increase in Î²-chemokine secretion in W278 and B195 cell cultures compared to controls (Table <xref ref-type="table" rid="T2">2</xref>).</p>
        <table-wrap position="float" id="T2">
          <label>Table 2</label>
          <caption>
            <p>Î²-chemokines produced by mitogen-activated CD4 T cells.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <td align="center">EU code</td>
                <td align="center">RANTES (ng/ml)</td>
                <td align="center">MIP1Î± (ng/ml)</td>
                <td align="center">MIP1Î² (ng/ml)</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center">W278</td>
                <td align="center">33.7</td>
                <td align="center">26.4</td>
                <td align="center">39.1</td>
              </tr>
              <tr>
                <td align="center">B195</td>
                <td align="center">19.7</td>
                <td align="center">56.3</td>
                <td align="center">66.8</td>
              </tr>
              <tr>
                <td colspan="4">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="center">Controls<sup>a</sup></td>
                <td align="center">14.1 (11.7â34.3)</td>
                <td align="center">30.6 (26.8â49.8)</td>
                <td align="center">58.3 (45.5â67.3)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><sup>a </sup>median and range for the 5 controls used in the experiments shown in figures 2 and 3.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>To investigate the possibility of enhanced sensitivity to Î²-chemokines, we infected non-stimulated CD4 T cells from subject B195 (not enough cells from subject W278 were available) in the presence of a cocktail of recombinant RANTES, MIP1Î± and MIP1Î² added at increasing concentrations. In the presence of low levels (â¤ 5 ng) of recombinant Î²-chemokines, HIV-1 replication was comparable in B195 and CCR5-wt control CD4 T cells (Fig. <xref ref-type="fig" rid="F3">3C</xref>), as already observed in the absence of added Î²-chemokines (Fig. <xref ref-type="fig" rid="F3">3B</xref>). In contrast, when the Î²-chemokine levels were increased, the efficiency of infection fell sharply in B195 CD4 T cells and far less markedly in control CD4 T cells (fig. <xref ref-type="fig" rid="F3">3C</xref>) (ID<sub>50 </sub>values were 8.12 Â± 1.58 ng/ml and 59.34 Â± 16.87 ng/ml for B195 and control respectively). CD4 T cell CCR5 surface expression was similar in the two individuals (data not shown). These results indicated that HIV infection of CD4 T cells from EU subject B195 was unusually susceptible to inhibition by Î²-chemokines.</p>
      </sec>
      <sec>
        <title>Pantropic restriction of HIV replication in subject W276 affects several lentiviruses</title>
        <p>The blockade of in vitro HIV infection in CD4 T cells from subject W276 was independent of viral tropism and of the entry pathway (fusion or endocytosis) (fig. <xref ref-type="fig" rid="F1">1</xref>). In a fluorimetric fusion assay with cells expressing HIV-1 envelope proteins [<xref ref-type="bibr" rid="B34">34</xref>], W276 CD4 T cells showed normal membrane fusion (not shown), further supporting post-entry restriction of viral replication in these cells.</p>
        <p>Previous qualitative PCR analysis of viral replication in CD4 T cells from subject W276 suggested that the restriction step occurred before integration [<xref ref-type="bibr" rid="B11">11</xref>], but early times post-infection were not analyzed. We therefore used single-round infection and real-time PCR to determine the precise stage at which the restriction occurred. Early reverse transcription products (R-U5) were far lower in W276 cells than in control cells, from the very first hours after infection (fig. <xref ref-type="fig" rid="F4">4A</xref>), and they increased very little during the time course of infection. Levels of PCR products corresponding to subsequent replication steps were also decreased (not shown). These results suggest that early post-entry steps of viral replication, most likely involving reverse transcription, are impaired in W276 CD4 T cells. Note that W276 CD4 T cells were readily activated by PHA (&gt;95% of cells were CD25+ at the time of challenge) thus discarding that the restriction of HIV-1 infection was caused by a defect of the response to PHA-stimulation. In addition, HIV-1 restriction in W276 CD4 T cells was not overcome by increasing the size of the inoculum of VSV-G pseudotyped HIV-1 (fig. <xref ref-type="fig" rid="F4">4B</xref>), arguing against a role of a saturable restriction factor.</p>
        <fig position="float" id="F4">
          <label>Figure 4</label>
          <caption>
            <p><bold>Pantropic restriction in CD4 T cells from subject W276 affects the replication of several retroviruses</bold>. <bold>A. </bold>Early reverse transcripts (RU5) analyzed by real-time PCR at various times after HIV-VSVG pseudotype challenge of CD4 T cells from subject W276 (open circles) and a representative control (filled triangles). <bold>B. </bold>Infection of CD4 T cells from subject W276 (open circles) and a control (filled triangles) with increasing amounts of HIV-VSVG pseudotype. Results (mean of three independent infections) are expressed as luciferase activity per second in cell lysates three days post-challenge. The control is representative of cells from three different controls. Error bars represent the standard deviation. <bold>C. </bold>Relative infection of CD4 T cells from subject W276 (white bars) by HIV-1, SIVmac and SIVagm particles pseudotyped with the VSVG fusion protein (n = 3, mean Â± SD). Luciferase activity in cell lysates from a representative control (black bars) was attributed a value of 100%.</p>
          </caption>
          <graphic xlink:href="1742-4690-3-81-4"/>
        </fig>
        <p>To determine whether the restriction of viral replication in CD4 T cells from subject W276 was specific to HIV-1 or also affected other lentiviruses, we challenged the cells with SIVagm and SIVmac luciferase reporter viruses (fig. <xref ref-type="fig" rid="F4">4C</xref>) pseudotyped with VSV-G. Replication of both viruses was strongly inhibited in W276 CD4 T cells.</p>
      </sec>
      <sec>
        <title>Persistence of HIV-1 restriction in primary cells from Vietnamese EUs</title>
        <p>To determine whether resistance to infection was transient or persistent, we tested primary CD4 T cells or PBMC obtained from the five EUs at various times during 2â6 years of follow-up. The samples included cells obtained from four of the subjects (W276, W278, W336 and B184) after alleged interruption of IV drug use (Table <xref ref-type="table" rid="T3">3</xref>). In infectivity assays with PHA-activated cells, HIV-1 replication was always inhibited in the EU cells compared to control cells. Moreover, the same pattern of HIV-1 inhibition (R5-restricted or tropism-independent) was observed in serial samples from each EU (not shown), confirming the persistence of individual restriction phenotypes.</p>
        <table-wrap position="float" id="T3">
          <label>Table 3</label>
          <caption>
            <p>Restriction in infectivity assays.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <td align="center">EU code</td>
                <td align="center">PBMC samples tested for HIV-1 infectivity<sup>a</sup></td>
                <td align="center">CD4 cell samples tested for HIV-1 infectivity<sup>a</sup></td>
                <td align="center">Restricted tropism<sup>b</sup></td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td/>
                <td align="center">Year (month)</td>
                <td align="center">Year (month)</td>
                <td/>
              </tr>
              <tr>
                <td colspan="4">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="center">W276</td>
                <td align="center">1999 (1, 7)</td>
                <td align="center">1998 (1), 1999 (1, 7), 2004 (6)</td>
                <td align="center">Pantropic</td>
              </tr>
              <tr>
                <td align="center">W278</td>
                <td align="center">1998 (1), 2000 (4)</td>
                <td align="center">1998 (1), 2000 (4, 8), 2004 (6)</td>
                <td align="center">R5 tropic</td>
              </tr>
              <tr>
                <td align="center">W336</td>
                <td align="center">1998 (1)</td>
                <td align="center">1998 (1), 2001 (1, 4)</td>
                <td align="center">R5 tropic</td>
              </tr>
              <tr>
                <td align="center">B184</td>
                <td align="center">1998 (11)</td>
                <td align="center">1998 (1, 11), 2004 (1)</td>
                <td align="center">R5 tropic</td>
              </tr>
              <tr>
                <td align="center">B195</td>
                <td align="center">1998 (1), 1999 (1)</td>
                <td align="center">1998 (11), 1999 (1, 7)</td>
                <td align="center">R5 tropic</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><sup>a </sup>Cell samples tested for HIV-1 susceptibility in single-round or productive infection. <sup>b </sup>Tropism associated with HIV-1 restriction (see figure 1).</p>
          </table-wrap-foot>
        </table-wrap>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>We have previously reported that CD4 T cells from some Vietnamese individuals who remain free of infection after several years of intravenous drug use show reduced susceptibility to HIV-1 infection [<xref ref-type="bibr" rid="B11">11</xref>]. Here we extended our investigations of the mechanisms underlying HIV-1 restriction in CD4 T cells and found that both entry and post-entry steps of HIV-1 replication could be affected. Interestingly, the restriction in one of these subjects also affected other lentiviruses. In addition, the restriction mechanisms persisted for several years.</p>
      <p>The same patterns of in vitro CD4 T cell resistance to HIV-1 infection were observed after alleged interruption of at-risk behaviors, suggesting that the mechanisms of resistance in these subjects do not depend on exposure to the virus but rather might be linked to constitutive factors. It is noteworthy in this respect that heterozygous CCR5 mutations in two of the five EUs studied here (B184 and W336) were associated with low CCR5 surface expression on their primary CD4 T cells and with resistance of these cells to HIV-1 R5 infection. CCR5Î32 heterozygosity has been associated with decreases both in CCR5 surface expression and in susceptibility to in vitro infection by R5 viruses, although to a lesser extent than CCR5Î32 homozygosity [<xref ref-type="bibr" rid="B35">35</xref>-<xref ref-type="bibr" rid="B37">37</xref>]. Low CCR5 expression in CCR5Î32 heterozygous cells has been attributed to several mechanisms, including sequestration of the wild-type molecule by the mutant molecule in the endoplasmic reticulum, and reduced gene dosage [<xref ref-type="bibr" rid="B37">37</xref>-<xref ref-type="bibr" rid="B39">39</xref>]. The molecular mechanisms underlying the reduced CCR5 expression in the heterozygous Vietnamese EUs' CD4 T cells are under investigation.</p>
      <p>CD4 T cells from subjects W278 and B195 were also resistant to infection by HIV-1 R5, even though these EUs had the wild-type CCR5 molecule. HIV restriction in these subjects' cells was abrogated by anti-Î²-chemokine Abs. Accordingly, PCR experiments suggested that the block in CD4 T cells from subjects W278 and B195 affected very early steps of viral replication [<xref ref-type="bibr" rid="B11">11</xref>], likely reflecting inhibition of viral entry by Î²-chemokine ligands of CCR5 [<xref ref-type="bibr" rid="B40">40</xref>]. Partial resistance to HIV-1 R5 in cells from some CCR5-wt EUs has previously been linked to decreased CCR5 expression on the CD4 T cell surface and to increased Î²-chemokine secretion [<xref ref-type="bibr" rid="B12">12</xref>]. CCR5 expression on CD4 T cells from subjects W278 and B195 was not subnormal. However, as CCR5 expression on thawed cells (including from controls) was too low for FACS analysis, our experiments were done 10 days after PHA stimulation and we cannot therefore formally exclude the possibility that CCR5 expression was reduced on W278 and B195 CD4 T cells at the time of infection (three days after PHA stimulation) and recovered rapidly thereafter. Nevertheless, Î²-chemokine secretion by CD4 T cells upon mitogen activation was not higher in the two EUs than in controls, suggesting that the inhibitory mechanism differs from those previously reported. Moreover, non-stimulated CD4 T cells from these two EUs expressed normal levels of CCR5 and allowed HIV-1 entry and replication. However, in these conditions, in which endogenous secretion of Î²-chemokines is very low, HIV-1 infection was inhibited by exogenous Î²-chemokines at lower concentrations than in experiments with control cells. Thus, HIV-1 inhibition in PHA-activated CD4 T cells appears to result from enhanced sensitivity to secreted Î²-chemokines. In the context of wild-type CCR5, this increased sensitivity might be governed by the chemoreceptor microenvironment, which has been shown to influence both CCR5 affinity for its agonists [<xref ref-type="bibr" rid="B41">41</xref>] and Î²-chemokine-induced CCR5 internalization [<xref ref-type="bibr" rid="B42">42</xref>].</p>
      <p>CD4 T cells from subject W276 exhibited a pantropic restriction phenotype independent of the virus entry pathway. Viral replication was blocked at early post-entry steps, probably through impaired reverse transcription. The restriction pattern in W276 cells (i.e. non-saturable, blockade of several lentiviruses) differed from that attributed to TRIM5Î± and APOBEC family proteins â restriction factors that also target early post-entry steps of viral replication [<xref ref-type="bibr" rid="B43">43</xref>-<xref ref-type="bibr" rid="B45">45</xref>]. Preliminary analyses of heterokaryons obtained by fusion of W276 CD4 T cells with the HIV-susceptible cell line A2.01 (data not shown) suggest that the restriction in EU W276 cells might be due to missing or defective cell factor(s) necessary for viral replication, rather than to antiviral molecules.</p>
      <p>Strong CD4 T cell resistance to HIV-1 infection is a highly unusual phenomenon and it is reportedly more frequent among EUs [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. These cells provide unique opportunities for identifying novel HIV-1 resistance mechanisms. For example, the CCR5Î32 homozygous genotype was first identified in two EUs with reduced susceptibility to HIV-1 infection [<xref ref-type="bibr" rid="B15">15</xref>], but has since been associated with protection in Caucasians [<xref ref-type="bibr" rid="B17">17</xref>] and has led to the development of CCR5-targeting drugs [<xref ref-type="bibr" rid="B46">46</xref>]. However, CCR5Î32 homozygosity accounts for cell resistance in only a small fraction of Caucasian EUs.</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>Each of the in vitro resistance mechanisms described here may contribute to protection against HIV-1 infection in exposed uninfected Vietnamese individuals, possibly in conjunction with other innate or adaptive antiviral responses [<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>]. Low CCR5 expression due to CCR5 mutations in target cells may limit the infection and spread of HIV-1 R5 viruses, which are preferentially transmitted and predominate in the early phases of the human infection [<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>]. Î²-chemokine-mediated resistance to HIV-1 R5 infection of activated CCR5-wt CD4 T cells could limit HIV-1 transmission and spread at preferential sites of viral replication. Indeed, HIV-1 replication occurs mainly in activated CD4 T cells, which tend to be located in Î²-chemokine-rich environments such as lymph nodes and gut-associated lymphoid tissue [<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>]. Finally, near-complete restriction of viral replication, as found in the cells of EU subject W276, probably protects against HIV-1 transmission, as in CCR5Î32 homozygous individuals. Identification of the mechanisms and molecules involved in such broad lentivirus restriction may lead to new viral and/or cellular targets for anti-HIV therapy.</p>
    </sec>
    <sec sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec>
        <title>Study subjects</title>
        <p>The five EUs studied here (Table <xref ref-type="table" rid="T1">1</xref>) belonged to a population of intravenous drug users (IDU) who had been exposed to HIV-1 through needle sharing for many years [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B53">53</xref>]. Subjects W276, W278, and B195 correspond to subjects EU1 to EU3 and subject B184 corresponds to subject EU13 in [<xref ref-type="bibr" rid="B11">11</xref>]. W336 was first described in [<xref ref-type="bibr" rid="B25">25</xref>]. When recruited, they had been using drugs for 17 to 26 years. All continued high-risk practices for several years despite medical counseling. Four subsequently said they had stopped at-risk drug use between 2000 and 2003 (Table <xref ref-type="table" rid="T1">1</xref>). Subject B195 was lost to follow-up in July 1999. Controls were Vietnamese (20) and European (7) healthy blood donors with a low risk of HIV-1 infection (Red Cross, Vietnam and Centre de Transfusion Sanguine Ile-de-France, Rungis, France). All the infectivity assays with EU CD4 T cells were performed in parallel with susceptible CD4 T cells from at least three randomly selected controls. All participants gave their informed consent.</p>
      </sec>
      <sec>
        <title>CD4 T cells</title>
        <p>Peripheral blood mononuclear cells (PBMC) from EUs and controls were isolated from whole blood by Ficoll-Hypaque centrifugation. CD4 cells were purified from thawed PBMC by positive selection with antibody-coated immunomagnetic beads (Miltenyi Biotech, France). Activated CD4 T cells (&gt;95% CD4+CD3+CD25+ as estimated by flow cytometry) were obtained after stimulation for three days with phytohemagglutinin (PHA, 1 Î¼g/ml) and interleukin-2 (IL2) (Chiron, France, 100 IU/ml) and were maintained in RPMI 1640 medium containing 10% fetal calf serum, penicillin/streptomycin (100 U/ml) and IL2.</p>
      </sec>
      <sec>
        <title>Production of reporter viral particles and infectious challenge</title>
        <p>Pseudotyped reporter retroviral particles were produced by transiently co-transfecting 293T cells with the proviral constructs pNL-Luc-E-R+, pSIVmac-Luc-E-R+ or pSIVagm-Luc-E-R+ [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B54">54</xref>] and the VSV-G, HxB2-Env, BaL-Env, JRFL-Env or YU2-Env expression vectors (7.5 Î¼g each) using the lipofection reagent SuperFect (Qiagen, France). Supernatants were harvested 48 h after transfection, and 10<sup>5 </sup>CD4 T cells were infected (m.o.i: 0.1â1.0) in triplicate in 96-well plates with a spinoculation protocol [<xref ref-type="bibr" rid="B55">55</xref>] (1 hour of centrifugation at room temperature at 1500 <italic>g</italic>, followed by 1 hour at 37Â°C). After challenge, cells were extensively washed and then cultured.</p>
      </sec>
      <sec>
        <title>Quantification of luciferase activity in cell lysates</title>
        <p>Three days after challenge the cells were harvested and lysed with 100 Î¼l of luciferase lysis buffer (Promega, France). Luciferase activity was quantified in 10 Î¼l of each lysate with the Promega Luciferase Assay System in a Veritas microplate luminometer (Turner BioSystems, CA, USA).</p>
      </sec>
      <sec>
        <title>CCR5 genotypic characterization</title>
        <p>DNA was extracted from PBMC with the DNeasy Tissue Kit (Qiagen, Courtaboeuf, France). The full-length coding region (exon 4) of the CCR5 gene was amplified with primers and in conditions described elsewhere [<xref ref-type="bibr" rid="B24">24</xref>].</p>
        <p>PCR products were purified with the ExoSAP-IT<sup>Â® </sup>enzyme for PCR Product Clean-Up (Pharmacia-Amersham, USA) and were directly sequenced with the BigDye Terminator cycle sequencing kit (ver.3.1; Applera, France). Sequences were determined with an automatic sequencer (ABI-Prism 3100, Applied Biosystem, USA) and analyzed with SeqScape software version 2.5 (Applied Biosystem, USA).</p>
      </sec>
      <sec>
        <title>Flow cytometry of CCR5 expression</title>
        <p>Ten days after PHA activation, CD4 T cells were incubated for 30 minutes at room temperature with CCR5-FITC (clone 2D7) (BD Bioscience, France) and analyzed on a Cytomics FC500 flow cytometer (Beckman Coulter, Paris, France).</p>
      </sec>
      <sec>
        <title>CCR5-mediated actin polymerisation</title>
        <p>Actin polymerization in CD4 T cells was measured as described elsewhere [<xref ref-type="bibr" rid="B30">30</xref>]. Briefly, ten days after PHA stimulation, cells (1 Ã 10<sup>7 </sup>cells/mL) were incubated in RPMI medium containing 20 mM HEPES in the presence or absence of inhibitor. RANTES (30 nM) was then added to the cell suspension. At each indicated time point (15 s to 2 min), a 50-Î¼L aliquot of cell suspension was mixed with 200 Î¼L of labeling buffer consisting of 10<sup>-7 </sup>M FITC-phalloidin (Sigma), 0.125 mg/mL L-Î±-lysophosphatidylcholine palmitoyl (Sigma) and 4.5% PFA in PBS. The kinetics of actin polymerization was monitored by means of flow cytometry. Results are expressed as follows: [MFI after addition of ligand/MFI before addition of ligand] Ã 100]. MFI values before ligand addition were arbitrarily set at 100%. Owing to the large number of cells required, CD4 T cells were amplified on irradiated heterologous feeder PBMC for two weeks prior to testing. The pattern of HIV-1 restriction in amplified cells was similar to that found in the primary CD4 T cells (not shown). TAK-779 was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.</p>
      </sec>
      <sec>
        <title>Quantification of secreted Î²-chemokines</title>
        <p>Levels of Î²-chemokines, RANTES, MIP-1Î± and MIP-1Î² in the supernatants of CD4 T cells were measured after 72 h of culture with or without PHA stimulation, by using commercial ELISA kits (Quantikine, R&amp;D systems, France).</p>
      </sec>
      <sec>
        <title>Real-time PCR quantification of HIV-1 replication intermediates</title>
        <p>Three days after PHA stimulation, CD4 T cells were challenged with DNase (Invitrogen, France)-pretreated viruses (1 h at room temperature). At the times indicated, 5 Ã 10<sup>5 </sup>cells were washed in PBS and lysed, then total DNA was extracted with the DNeasy Tissue Kit (Qiagen, France). Early HIV-1 reverse transcription products were quantified with an ABI PRISM 7000 instrument (Applied Biosystems, France) using specific primers and probe as previously described [<xref ref-type="bibr" rid="B56">56</xref>]. One hundred nanograms of template DNA was used per reaction, and the albumin gene was used as a housekeeping gene to normalize sample input. 8E5 cells containing one integrated copy of HIV-1 per cell [<xref ref-type="bibr" rid="B57">57</xref>] were used to construct standard curves.</p>
      </sec>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The author(s) declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>ASC, LT, FBS and GP conceived the study and contributed to its experimental design and coordination. DSA participated in the design of the study. ASC, PV, LC and WC performed the experiments. ASC, LC, WC, DSA and GP participated in the data analysis. ASC and GP drafted the manuscript. All the authors critically reviewed and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>We thank Luong Thu Tram and Nguyen Van Ngai for follow-up of the exposed uninfected individuals, Annie David for technical assistance, Nathaniel Landau and Jay Levy for the gift of plasmids and vectors, and Ioannis Theodorou for advice and help in CCR5 genotyping.</p>
        <p>This work was supported by the French National Agency for AIDS Research (ANRS) (#1268 and 2005/194) and Sidaction (#50007-02-00/AO16-2). ASC was the recipient of postdoctoral fellowships from ANRS and Sidaction.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wainberg</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Blain</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fitz-Gibbon</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Differential susceptibility of human lymphocyte cultures to infection by HIV</article-title>
          <source>Clin Exp Immunol</source>
          <year>1987</year>
          <volume>70</volume>
          <fpage>136</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="pmid">2826057</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ciuffi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bleiber</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Munoz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Loeuillet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rehr</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gunthard</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Oxenius</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Meylan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonhoeffer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Trono</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Telenti</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection</article-title>
          <source>J Virol</source>
          <year>2004</year>
          <volume>78</volume>
          <fpage>10747</fpage>
          <lpage>10754</lpage>
          <pub-id pub-id-type="pmid">15367641</pub-id>
          <pub-id pub-id-type="doi">10.1128/JVI.78.19.10747-10754.2004</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greene</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Peterlin</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy</article-title>
          <source>Nat Med</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>673</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="pmid">12091904</pub-id>
          <pub-id pub-id-type="doi">10.1038/nm0702-673</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goff</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>Retrovirus restriction factors</article-title>
          <source>Mol Cell</source>
          <year>2004</year>
          <volume>16</volume>
          <fpage>849</fpage>
          <lpage>859</lpage>
          <pub-id pub-id-type="pmid">15610729</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.molcel.2004.12.001</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiu</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Soros</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Kreisberg</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Stopak</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yonemoto</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>WC</given-names>
            </name>
          </person-group>
          <article-title>Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells</article-title>
          <source>Nature</source>
          <year>2005</year>
          <volume>435</volume>
          <fpage>108</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="pmid">15829920</pub-id>
          <pub-id pub-id-type="doi">10.1038/nature03493</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ganesh</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Burstein</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Guha-Niyogi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Louder</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Mascola</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Klomp</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Wijmenga</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Duckett</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Nabel</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes</article-title>
          <source>Nature</source>
          <year>2003</year>
          <volume>426</volume>
          <fpage>853</fpage>
          <lpage>857</lpage>
          <pub-id pub-id-type="pmid">14685242</pub-id>
          <pub-id pub-id-type="doi">10.1038/nature02171</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawyer</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>LI</given-names>
            </name>
            <name>
              <surname>Akey</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Emerman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Malik</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans</article-title>
          <source>Curr Biol</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>95</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="pmid">16401428</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.cub.2005.11.045</pub-id>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Speelmon</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Livingston-Rosanoff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Vu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Bui</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Geraghty</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>McElrath</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection</article-title>
          <source>J Virol</source>
          <year>2006</year>
          <volume>80</volume>
          <fpage>2463</fpage>
          <lpage>2471</lpage>
          <pub-id pub-id-type="pmid">16474153</pub-id>
          <pub-id pub-id-type="doi">10.1128/JVI.80.5.2463-2471.2006</pub-id>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paxton</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Tse</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Skurnick</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>VanDevanter</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Padian</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Kotler</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Wolinsky</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Koup</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure</article-title>
          <source>Nat Med</source>
          <year>1996</year>
          <volume>2</volume>
          <fpage>412</fpage>
          <lpage>417</lpage>
          <pub-id pub-id-type="pmid">8597950</pub-id>
          <pub-id pub-id-type="doi">10.1038/nm0496-412</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Connor</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Paxton</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Sheridan</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Koup</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Macrophages and CD4+ T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1</article-title>
          <source>J Virol</source>
          <year>1996</year>
          <volume>70</volume>
          <fpage>8758</fpage>
          <lpage>8764</lpage>
          <pub-id pub-id-type="pmid">8971004</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Truong</surname>
              <given-names>LX</given-names>
            </name>
            <name>
              <surname>Luong</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Scott-Algara</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Versmisse</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Perez-Bercoff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Tran</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Fontanet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Follezou</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Theodorou</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Barre-Sinoussi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pancino</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>CD4 cell and CD8 cell-mediated resistance to HIV-1 infection in exposed uninfected intravascular drug users in Vietnam</article-title>
          <source>Aids</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>1425</fpage>
          <lpage>1434</lpage>
          <pub-id pub-id-type="pmid">12824779</pub-id>
          <pub-id pub-id-type="doi">10.1097/00002030-200307040-00002</pub-id>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paxton</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gingeras</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Landau</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Mackay</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Koup</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines</article-title>
          <source>Virology</source>
          <year>1998</year>
          <volume>244</volume>
          <fpage>66</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">9581779</pub-id>
          <pub-id pub-id-type="doi">10.1006/viro.1998.9082</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Butera</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Pisell</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Limpakarnjanarat</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Mastro</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Folks</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Production of a novel viral suppressive activity associated with resistance to infection among female sex workers exposed to HIV type 1</article-title>
          <source>AIDS Res Hum Retroviruses</source>
          <year>2001</year>
          <volume>17</volume>
          <fpage>735</fpage>
          <lpage>744</lpage>
          <pub-id pub-id-type="pmid">11429113</pub-id>
          <pub-id pub-id-type="doi">10.1089/088922201750237004</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eyeson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Boaz</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Sefia</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tomkins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Waters</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Easterbrook</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Vyakarnam</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIV-exposed-seronegative subjects</article-title>
          <source>Aids</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>2299</fpage>
          <lpage>2311</lpage>
          <pub-id pub-id-type="pmid">14571181</pub-id>
          <pub-id pub-id-type="doi">10.1097/00002030-200311070-00004</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Paxton</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Choe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ceradini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Horuk</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>MacDonald</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Stuhlmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Koup</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Landau</surname>
              <given-names>NR</given-names>
            </name>
          </person-group>
          <article-title>Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection</article-title>
          <source>Cell</source>
          <year>1996</year>
          <volume>86</volume>
          <fpage>367</fpage>
          <lpage>377</lpage>
          <pub-id pub-id-type="pmid">8756719</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80110-5</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quillent</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Oberlin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rousset</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gonzalez-Canali</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Metais</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Montagnier</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Virelizier</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Arenzana-Seisdedos</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Beretta</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene</article-title>
          <source>Lancet</source>
          <year>1998</year>
          <volume>351</volume>
          <fpage>14</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="pmid">9433423</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(97)09185-X</pub-id>
        </citation>
      </ref>
      <ref id="B17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Samson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Libert</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Doranz</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Rucker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liesnard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Farber</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Saragosti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lapoumeroulie</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cognaux</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Forceille</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Verhofstede</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Burtonboy</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Georges</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rana</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Smyth</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Collman</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Doms</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Vassart</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Parmentier</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene</article-title>
          <source>Nature</source>
          <year>1996</year>
          <volume>382</volume>
          <fpage>722</fpage>
          <lpage>725</lpage>
          <pub-id pub-id-type="pmid">8751444</pub-id>
          <pub-id pub-id-type="doi">10.1038/382722a0</pub-id>
        </citation>
      </ref>
      <ref id="B18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koning</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Dekker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kaslow</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Dukers</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>van Baarle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Prins</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schuitemaker</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour</article-title>
          <source>Aids</source>
          <year>2004</year>
          <volume>18</volume>
          <fpage>1117</fpage>
          <lpage>1126</lpage>
          <pub-id pub-id-type="pmid">15166527</pub-id>
          <pub-id pub-id-type="doi">10.1097/00002030-200405210-00005</pub-id>
        </citation>
      </ref>
      <ref id="B19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garzino-Demo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Margolick</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Cleghorn</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sill</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Blattner</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Cocchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Carlo</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>DeVico</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>11986</fpage>
          <lpage>11991</lpage>
          <pub-id pub-id-type="pmid">10518563</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.96.21.11986</pub-id>
        </citation>
      </ref>
      <ref id="B20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furci</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scarlatti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Burastero</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tambussi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Colognesi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Quillent</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Longhi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Loverro</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Borgonovo</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gaffi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Carrow</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Malnati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lusso</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Siccardi</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Lazzarin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beretta</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele</article-title>
          <source>J Exp Med</source>
          <year>1997</year>
          <volume>186</volume>
          <fpage>455</fpage>
          <lpage>460</lpage>
          <pub-id pub-id-type="pmid">9236198</pub-id>
          <pub-id pub-id-type="doi">10.1084/jem.186.3.455</pub-id>
        </citation>
      </ref>
      <ref id="B21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stranford</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Skurnick</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Louria</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Osmond</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Sninsky</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Weinhold</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lindquist</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>1030</fpage>
          <lpage>1035</lpage>
          <pub-id pub-id-type="pmid">9927688</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.96.3.1030</pub-id>
        </citation>
      </ref>
      <ref id="B22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>John</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Arango-Jaramillo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Finny</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Risk associated HIV-1 cross-clade resistance of whole peripheral blood mononuclear cells from exposed uninfected individuals with wild-type CCR5</article-title>
          <source>J Acquir Immune Defic Syndr</source>
          <year>2004</year>
          <volume>35</volume>
          <fpage>1</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">14707786</pub-id>
        </citation>
      </ref>
      <ref id="B23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaul</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rowland-Jones</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Kimani</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Kiama</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rostron</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Njagi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bwayo</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>MacDonald</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>McMichael</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Plummer</surname>
              <given-names>FA</given-names>
            </name>
          </person-group>
          <article-title>Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses</article-title>
          <source>J Clin Invest</source>
          <year>2001</year>
          <volume>107</volume>
          <fpage>341</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="pmid">11160158</pub-id>
        </citation>
      </ref>
      <ref id="B24">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Capoulade-Metay</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Truong</surname>
              <given-names>LX</given-names>
            </name>
            <name>
              <surname>Dudoit</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Versmisse</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Scott-Algara</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barre-Sinoussi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Debre</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bismuth</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pancino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Theodorou</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia</article-title>
          <source>Aids</source>
          <year>2004</year>
          <volume>18</volume>
          <fpage>2243</fpage>
          <lpage>2252</lpage>
          <pub-id pub-id-type="pmid">15577536</pub-id>
          <pub-id pub-id-type="doi">10.1097/00002030-200411190-00004</pub-id>
        </citation>
      </ref>
      <ref id="B25">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magierowska</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lepage</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lien</surname>
              <given-names>TX</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Guillotel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Issafras</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Reynes</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Fleury</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Follezou</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Debre</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Theodorou</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Barre-Sinoussi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Novel variant of the CCR5 gene in a Vietnamese population</article-title>
          <source>Microbes Infect</source>
          <year>1999</year>
          <volume>1</volume>
          <fpage>123</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">10917742</pub-id>
          <pub-id pub-id-type="doi">10.1016/S1286-4579(99)80002-1</pub-id>
        </citation>
      </ref>
      <ref id="B26">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blanpain</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vakili</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Doranz</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Govaerts</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Migeotte</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sharron</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dupriez</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Vassart</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Doms</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Parmentier</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity</article-title>
          <source>J Biol Chem</source>
          <year>1999</year>
          <volume>274</volume>
          <fpage>18902</fpage>
          <lpage>18908</lpage>
          <pub-id pub-id-type="pmid">10383387</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.274.27.18902</pub-id>
        </citation>
      </ref>
      <ref id="B27">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aiken</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A</article-title>
          <source>J Virol</source>
          <year>1997</year>
          <volume>71</volume>
          <fpage>5871</fpage>
          <lpage>5877</lpage>
          <pub-id pub-id-type="pmid">9223476</pub-id>
        </citation>
      </ref>
      <ref id="B28">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Mettling</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Portales</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Reant</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Clot</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Corbeau</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>G-protein signaling triggered by R5 human immunodeficiency virus type 1 increases virus replication efficiency in primary T lymphocytes</article-title>
          <source>J Virol</source>
          <year>2005</year>
          <volume>79</volume>
          <fpage>7938</fpage>
          <lpage>7941</lpage>
          <pub-id pub-id-type="pmid">15919952</pub-id>
          <pub-id pub-id-type="doi">10.1128/JVI.79.12.7938-7941.2005</pub-id>
        </citation>
      </ref>
      <ref id="B29">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Misse</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gajardo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Oblet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Religa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Riquet</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mathieu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yssel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Veas</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Soluble HIV-1 gp120 enhances HIV-1 replication in non-dividing CD4+ T cells, mediated via cell signaling and Tat cofactor overexpression</article-title>
          <source>Aids</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>897</fpage>
          <lpage>905</lpage>
          <pub-id pub-id-type="pmid">15905670</pub-id>
        </citation>
      </ref>
      <ref id="B30">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balabanian</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Harriague</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Decrion</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lagane</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Shorte</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Baleux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Virelizier</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Arenzana-Seisdedos</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chakrabarti</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes</article-title>
          <source>J Immunol</source>
          <year>2004</year>
          <volume>173</volume>
          <fpage>7150</fpage>
          <lpage>7160</lpage>
          <pub-id pub-id-type="pmid">15585836</pub-id>
        </citation>
      </ref>
      <ref id="B31">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baba</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Kanzaki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sawada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iizawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shiraishi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aramaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Okonogi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Meguro</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujino</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>5698</fpage>
          <lpage>5703</lpage>
          <pub-id pub-id-type="pmid">10318947</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.96.10.5698</pub-id>
        </citation>
      </ref>
      <ref id="B32">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharpless</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Verdin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kufta</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Dubois-Dalcq</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism</article-title>
          <source>J Virol</source>
          <year>1992</year>
          <volume>66</volume>
          <fpage>2588</fpage>
          <lpage>2593</lpage>
          <pub-id pub-id-type="pmid">1548785</pub-id>
        </citation>
      </ref>
      <ref id="B33">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Westervelt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Trowbridge</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Epstein</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Blumberg</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Ratner</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo</article-title>
          <source>J Virol</source>
          <year>1992</year>
          <volume>66</volume>
          <fpage>2577</fpage>
          <lpage>2582</lpage>
          <pub-id pub-id-type="pmid">1548783</pub-id>
        </citation>
      </ref>
      <ref id="B34">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chanel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Staropoli</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Baleux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Amara</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Valenzuela-Fernandez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Virelizier</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Arenzana-Seisdedos</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Altmeyer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Low levels of co-receptor CCR5 are sufficient to permit HIV envelope-mediated fusion with resting CD4 T cells</article-title>
          <source>Aids</source>
          <year>2002</year>
          <volume>16</volume>
          <fpage>2337</fpage>
          <lpage>2340</lpage>
          <pub-id pub-id-type="pmid">12441808</pub-id>
          <pub-id pub-id-type="doi">10.1097/00002030-200211220-00016</pub-id>
        </citation>
      </ref>
      <ref id="B35">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Paxton</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Kassam</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ruffing</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rottman</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Choe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sodroski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Newman</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Koup</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Mackay</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro</article-title>
          <source>J Exp Med</source>
          <year>1997</year>
          <volume>185</volume>
          <fpage>1681</fpage>
          <lpage>1691</lpage>
          <pub-id pub-id-type="pmid">9151905</pub-id>
          <pub-id pub-id-type="doi">10.1084/jem.185.9.1681</pub-id>
        </citation>
      </ref>
      <ref id="B36">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pettoello-Mantovani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goldstein</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Decreased susceptibility of peripheral blood mononuclear cells from individuals heterozygous for a mutant CCR5 allele to HIV infection</article-title>
          <source>J Acquir Immune Defic Syndr Hum Retrovirol</source>
          <year>1998</year>
          <volume>19</volume>
          <fpage>145</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="pmid">9768623</pub-id>
        </citation>
      </ref>
      <ref id="B37">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Venkatesan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Petrovic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van Ryk</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Locati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weissman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration</article-title>
          <source>J Biol Chem</source>
          <year>2002</year>
          <volume>277</volume>
          <fpage>2287</fpage>
          <lpage>2301</lpage>
          <pub-id pub-id-type="pmid">11604406</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M108321200</pub-id>
        </citation>
      </ref>
      <ref id="B38">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benkirane</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Chun</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Koup</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Jeang</surname>
              <given-names>KT</given-names>
            </name>
          </person-group>
          <article-title>Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32</article-title>
          <source>J Biol Chem</source>
          <year>1997</year>
          <volume>272</volume>
          <fpage>30603</fpage>
          <lpage>30606</lpage>
          <pub-id pub-id-type="pmid">9388191</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.272.49.30603</pub-id>
        </citation>
      </ref>
      <ref id="B39">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alizon</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>46975</fpage>
          <lpage>46982</lpage>
          <pub-id pub-id-type="pmid">11600494</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M106432200</pub-id>
        </citation>
      </ref>
      <ref id="B40">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cocchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>DeVico</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Garzino-Demo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arya</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Lusso</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells</article-title>
          <source>Science</source>
          <year>1995</year>
          <volume>270</volume>
          <fpage>1811</fpage>
          <lpage>1815</lpage>
          <pub-id pub-id-type="pmid">8525373</pub-id>
          <pub-id pub-id-type="doi">10.1126/science.270.5243.1811</pub-id>
        </citation>
      </ref>
      <ref id="B41">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Taub</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol is essential for macrophage inflammatory protein 1 beta binding and conformational integrity of CC chemokine receptor 5</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>4298</fpage>
          <lpage>4306</lpage>
          <pub-id pub-id-type="pmid">12036855</pub-id>
          <pub-id pub-id-type="doi">10.1182/blood-2001-11-0087</pub-id>
        </citation>
      </ref>
      <ref id="B42">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Venkatesan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Lodge</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4</article-title>
          <source>Mol Biol Cell</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>3305</fpage>
          <lpage>3324</lpage>
          <pub-id pub-id-type="pmid">12925765</pub-id>
          <pub-id pub-id-type="doi">10.1091/mbc.E02-11-0714</pub-id>
        </citation>
      </ref>
      <ref id="B43">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mariani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schrofelbauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Navarro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Konig</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bollman</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Munk</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nymark-McMahon</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Landau</surname>
              <given-names>NR</given-names>
            </name>
          </person-group>
          <article-title>Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif</article-title>
          <source>Cell</source>
          <year>2003</year>
          <volume>114</volume>
          <fpage>21</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">12859895</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(03)00515-4</pub-id>
        </citation>
      </ref>
      <ref id="B44">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stremlau</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Owens</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Perron</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kiessling</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Autissier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sodroski</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys</article-title>
          <source>Nature</source>
          <year>2004</year>
          <volume>427</volume>
          <fpage>848</fpage>
          <lpage>853</lpage>
          <pub-id pub-id-type="pmid">14985764</pub-id>
          <pub-id pub-id-type="doi">10.1038/nature02343</pub-id>
        </citation>
      </ref>
      <ref id="B45">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hatziioannou</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Perez-Caballero</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cowan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bieniasz</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
          <article-title>Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>10774</fpage>
          <lpage>10779</lpage>
          <pub-id pub-id-type="pmid">15249685</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.0402361101</pub-id>
        </citation>
      </ref>
      <ref id="B46">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ray</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Doms</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>HIV-1 coreceptors and their inhibitors</article-title>
          <source>Curr Top Microbiol Immunol</source>
          <year>2006</year>
          <volume>303</volume>
          <fpage>97</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="pmid">16570858</pub-id>
        </citation>
      </ref>
      <ref id="B47">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kulkarni</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Butera</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Duerr</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals</article-title>
          <source>AIDS Rev</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>87</fpage>
          <lpage>103</lpage>
          <pub-id pub-id-type="pmid">12876898</pub-id>
        </citation>
      </ref>
      <ref id="B48">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott-Algara</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Truong</surname>
              <given-names>LX</given-names>
            </name>
            <name>
              <surname>Versmisse</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Luong</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Theodorou</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Barre-Sinoussi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pancino</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users</article-title>
          <source>J Immunol</source>
          <year>2003</year>
          <volume>171</volume>
          <fpage>5663</fpage>
          <lpage>5667</lpage>
          <pub-id pub-id-type="pmid">14634071</pub-id>
        </citation>
      </ref>
      <ref id="B49">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Koup</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Genotypic and phenotypic characterization of HIV-1 patients with primary infection</article-title>
          <source>Science</source>
          <year>1993</year>
          <volume>261</volume>
          <fpage>1179</fpage>
          <lpage>1181</lpage>
          <pub-id pub-id-type="pmid">8356453</pub-id>
          <pub-id pub-id-type="doi">10.1126/science.8356453</pub-id>
        </citation>
      </ref>
      <ref id="B50">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van't Wout</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Kootstra</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Mulder-Kampinga</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Albrecht-van Lent</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Scherpbier</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Veenstra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Boer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Coutinho</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Miedema</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schuitemaker</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission</article-title>
          <source>J Clin Invest</source>
          <year>1994</year>
          <volume>94</volume>
          <fpage>2060</fpage>
          <lpage>2067</lpage>
          <pub-id pub-id-type="pmid">7962552</pub-id>
        </citation>
      </ref>
      <ref id="B51">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pantaleo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Graziosi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Butini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pizzo</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Schnittman</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Kotler</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Fauci</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Lymphoid organs function as major reservoirs for human immunodeficiency virus</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1991</year>
          <volume>88</volume>
          <fpage>9838</fpage>
          <lpage>9842</lpage>
          <pub-id pub-id-type="pmid">1682922</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.88.21.9838</pub-id>
        </citation>
      </ref>
      <ref id="B52">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veazey</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Marx</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Lackner</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>The mucosal immune system: primary target for HIV infection and AIDS</article-title>
          <source>Trends Immunol</source>
          <year>2001</year>
          <volume>22</volume>
          <fpage>626</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="pmid">11698224</pub-id>
          <pub-id pub-id-type="doi">10.1016/S1471-4906(01)02039-7</pub-id>
        </citation>
      </ref>
      <ref id="B53">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Follezou</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>NY</given-names>
            </name>
            <name>
              <surname>Lien</surname>
              <given-names>TX</given-names>
            </name>
            <name>
              <surname>Lafon</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Tram</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Hung</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Aknine</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Lowenstein</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ngai</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Theodorou</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Delfraissy</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Debre</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fleury</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Barre-Sinoussi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>NH</given-names>
            </name>
          </person-group>
          <article-title>Clinical and biological characteristics of human immunodeficiency virus-infected and uninfected intravascular drug users in Ho Chi Minh City, Vietnam</article-title>
          <source>Am J Trop Med Hyg</source>
          <year>1999</year>
          <volume>61</volume>
          <fpage>420</fpage>
          <lpage>424</lpage>
          <pub-id pub-id-type="pmid">10497983</pub-id>
        </citation>
      </ref>
      <ref id="B54">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Connor</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Choe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Landau</surname>
              <given-names>NR</given-names>
            </name>
          </person-group>
          <article-title>Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes</article-title>
          <source>Virology</source>
          <year>1995</year>
          <volume>206</volume>
          <fpage>935</fpage>
          <lpage>944</lpage>
          <pub-id pub-id-type="pmid">7531918</pub-id>
          <pub-id pub-id-type="doi">10.1006/viro.1995.1016</pub-id>
        </citation>
      </ref>
      <ref id="B55">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Doherty</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Swiggard</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Malim</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding</article-title>
          <source>J Virol</source>
          <year>2000</year>
          <volume>74</volume>
          <fpage>10074</fpage>
          <lpage>10080</lpage>
          <pub-id pub-id-type="pmid">11024136</pub-id>
          <pub-id pub-id-type="doi">10.1128/JVI.74.21.10074-10080.2000</pub-id>
        </citation>
      </ref>
      <ref id="B56">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rouet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ekouevi</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Chaix</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Burgard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Inwoley</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tony</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Danel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Anglaret</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Leroy</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Msellati</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dabis</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rouzioux</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting</article-title>
          <source>J Clin Microbiol</source>
          <year>2005</year>
          <volume>43</volume>
          <fpage>2709</fpage>
          <lpage>2717</lpage>
          <pub-id pub-id-type="pmid">15956387</pub-id>
          <pub-id pub-id-type="doi">10.1128/JCM.43.6.2709-2717.2005</pub-id>
        </citation>
      </ref>
      <ref id="B57">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Folks</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Powell</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lightfoote</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koenig</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fauci</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Benn</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rabson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Daugherty</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gendelman</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Hoggan</surname>
              <given-names>MD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus</article-title>
          <source>J Exp Med</source>
          <year>1986</year>
          <volume>164</volume>
          <fpage>280</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="pmid">3014036</pub-id>
          <pub-id pub-id-type="doi">10.1084/jem.164.1.280</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>